Repligen to Report Third Quarter 2024 Financial Results
Repligen (NASDAQ:RGEN) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, before market open, followed by a conference call at 8:30 a.m. ET. CEO Olivier Loeillot mentioned that the team is working to complete previously disclosed revenue restatements from September 18. The company plans to file amended periodic reports along with the Q3 2024 results. The conference call will be accessible via toll-free numbers and webcast through the company's Investor Relations section, with replay options available using passcode 3384562.
Repligen (NASDAQ:RGEN) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024, prima dell'apertura del mercato, seguito da una conference call alle 8:30 a.m. ET. Il CEO Olivier Loeillot ha menzionato che il team sta lavorando per completare le rettifiche dei ricavi precedentemente comunicate il 18 settembre. L'azienda prevede di presentare rapporti periodici modificati insieme ai risultati del Q3 2024. La conference call sarà accessibile tramite numeri gratuiti e live streaming attraverso la sezione Relazioni con gli Investitori dell'azienda, con opzioni di riproduzione disponibili utilizzando il codice di accesso 3384562.
Repligen (NASDAQ:RGEN) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024, antes de la apertura del mercado, seguido de una llamada de conferencia a las 8:30 a.m. ET. El CEO Olivier Loeillot mencionó que el equipo está trabajando para completar las reexpresiones de ingresos previamente divulgadas el 18 de septiembre. La empresa planea presentar informes periódicos enmendados junto con los resultados del tercer trimestre de 2024. La llamada de conferencias será accesible a través de números gratuitos y una transmisión web a través de la sección de Relaciones con Inversores de la empresa, con opciones de repetición disponibles utilizando el código de acceso 3384562.
Repligen (NASDAQ:RGEN)은 2024년 11월 12일 화요일, 시장 개장 전에 3분기 재무 결과 발표를 예정하고 있으며, 오전 8시 30분(동부 표준시)에 컨퍼런스 콜이 이어질 예정입니다. CEO 올리비에 로엘로는 팀이 9월 18일에 발표된 수익 재구성을 완료하기 위해 작업 중이라고 언급했습니다. 회사는 2024년 3분기 결과와 함께 수정된 정기 보고서를 제출할 계획입니다. 컨퍼런스 콜은 무료 전화번호와 회사의 투자자 관계 섹션을 통해 웹캐스트 방식으로 접근할 수 있으며, 3384562 패스코드를 이용한 재생 옵션도 제공됩니다.
Repligen (NASDAQ:RGEN) a prévu l'annonce de ses résultats financiers pour le troisième trimestre 2024 pour le mardi 12 novembre 2024, avant l'ouverture du marché, suivie d'une conférence téléphonique à 8h30 HE. Le PDG Olivier Loeillot a mentionné que l'équipe travaille à finaliser les révisions de revenus précédemment divulguées le 18 septembre. L'entreprise prévoit de déposer des rapports périodiques modifiés avec les résultats du T3 2024. La conférence téléphonique sera accessible via des numéros sans frais et en direct sur le site des Relations Investisseurs de l'entreprise, avec des options de rediffusion disponibles en utilisant le code d'accès 3384562.
Repligen (NASDAQ:RGEN) hat die Bekanntgabe der finanziellen Ergebnisse des dritten Quartals 2024 für Dienstag, den 12. November 2024, vor Markteröffnung angesetzt, gefolgt von einer Telefonkonferenz um 8:30 Uhr ET. CEO Olivier Loeillot erwähnte, dass das Team daran arbeitet, die zuvor am 18. September offengelegten Umsatzkorrekturen abzuschließen. Das Unternehmen plant, zusammen mit den Ergebnissen des Q3 2024 geänderte regelmäßige Berichte einzureichen. Die Telefonkonferenz wird über gebührenfreie Nummern und einen Webcast über den Bereich Investor Relations des Unternehmens zugänglich sein, mit Wiedergabeoptionen, die den Zugangscode 3384562 nutzen.
- None.
- Company is undergoing revenue restatements, indicating potential accounting issues
- Need to file amended periodic reports suggests previous financial statements were inaccurate
Insights
The upcoming earnings report carries heightened significance due to the pending revenue restatements announced in September. The mention of "required revenue restatements" signals potential accounting irregularities that could materially impact historical financial statements. This situation warrants careful scrutiny from investors, particularly regarding:
- The scope and magnitude of the restatements
- Impact on historical revenue recognition practices
- Potential changes to internal controls and accounting procedures
- Effects on investor confidence and market perception
The timing of both the restatements and Q3 results on the same day suggests a comprehensive financial update that could significantly influence the stock's trading trajectory. Investors should pay close attention to management's explanations during the conference call regarding both the restatements and current business performance.
Webcast and Conference Call to Be Held Tuesday, November 12, 2024, at 8:30 a.m. ET
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required revenue restatements and to announce our third quarter of 2024 results on Tuesday, November 12. We look forward to sharing our quarterly results and discussing our business performance at that time.”
The third quarter of 2024 conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 3384562.
More detailed information on the September 18, 2024 revenue restatements disclosure can be found here: Form 8-K and Supplement.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions as well as statements regarding the expected impact of the restatement and change in accounting treatment, including on the Company’s overall business operations, previously reported cash and cash equivalent balances, and strategic outlook are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, that the Company has underestimated the scope and impact of the restatement, risks and uncertainties around the effectiveness of the Company’s disclosure controls and procedures and the effectiveness of the Company’s internal control over financial reporting, the risk that the Company’s restated financial statements may take longer to complete than expected, as well as those risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including its 2023 Annual Report, its Current Reports on Form 8-K, its Quarterly Reports on Form 10-Q, including for the quarters ended March 31, 2024 and June 30, 2024, and in any subsequent filings with the Commission, which are available at the Commission’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect the Company’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on the Company’s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. As noted in the September 18, 2024 Form 8-K, investors are cautioned that the Prior Period Financial Statements (as defined therein), and related investor communications, should no longer be relied upon; such communications include earnings releases, press releases, shareholder communications, investor presentations and other communications describing relevant portions of the Prior Period Financial Statements.
Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
When will Repligen (RGEN) report Q3 2024 earnings?
What revenue restatements is Repligen (RGEN) working on?
How can investors access Repligen's (RGEN) Q3 2024 earnings call?
